Pub Date : 2015-09-01Epub Date: 2015-10-09DOI: 10.1016/j.eii.2015.09.002
L. Carrión-Martín , G. Pérez-Rial , A.I. Hernando-Alonso , L. Menchén-Viso , J. Pajares-Díaz , F.J. López-Longo , M. Valerio , M.J. Penalva-Moreno , I. Marín-Jimenez
Extra-intestinal manifestations are frequent in Crohn's disease (CD). Adult onset Still's disease is a rare disease presenting with arthritis and arthralgia, high ( > 39 °C) and persistent fever, rash, sore throat, lymphadenopathies and hepatosplenomegaly. There are only 3 cases in literature of adult onset Still's disease presenting in CD patients. We describe a new case of adult onset Still's disease associated to connective tissue disease. Although infrequent, it is important to become aware of this disease for the differential diagnosis of arthralgia and high fever in CD patients.
{"title":"Fiebre persistente en paciente con enfermedad de Crohn: enfermedad de Still del adulto","authors":"L. Carrión-Martín , G. Pérez-Rial , A.I. Hernando-Alonso , L. Menchén-Viso , J. Pajares-Díaz , F.J. López-Longo , M. Valerio , M.J. Penalva-Moreno , I. Marín-Jimenez","doi":"10.1016/j.eii.2015.09.002","DOIUrl":"10.1016/j.eii.2015.09.002","url":null,"abstract":"<div><p>Extra-intestinal manifestations are frequent in Crohn's disease (CD). Adult onset Still's disease is a rare disease presenting with arthritis and arthralgia, high (<!--> <!-->><!--> <!-->39<!--> <!-->°C) and persistent fever, rash, sore throat, lymphadenopathies and hepatosplenomegaly. There are only 3 cases in literature of adult onset Still's disease presenting in CD patients. We describe a new case of adult onset Still's disease associated to connective tissue disease. Although infrequent, it is important to become aware of this disease for the differential diagnosis of arthralgia and high fever in CD patients.</p></div>","PeriodicalId":100473,"journal":{"name":"Enfermedad Inflamatoria Intestinal al Día","volume":"14 3","pages":"Pages 105-108"},"PeriodicalIF":0.0,"publicationDate":"2015-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.eii.2015.09.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90874609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-09-01Epub Date: 2015-09-19DOI: 10.1016/j.eii.2015.08.002
A. Campos Ruiz , P. Ramirez de la Piscina Urraca , I. Ganchegui Aguirre , L. Urtasun Arlegui , A. Sanchez Patón , K. Spicakova , I.M. Duca Duca , S. Estrada Oncins , E. Delgado Fontaneda , M. Salvador Perez , B. Rodriguez Vigil
Inflammatory bowel disease (IBD) is a systemic chronic disease, which in some cases is associated with thromboembolic events. Although these events are uncommon, they are increased in patients with IBD and increase morbidity and mortality.While IBD is active there are modifications in the coagulation system, thus inducing a hypercoagulable state and a risk of developing thrombotic events which are not present in patients with inactive IBD.It is essential to identify which patients have a higher risk of developing a thrombotic event and establish appropriate prophylaxis as early as possible.We present some cases of patients diagnosed with IBD who developed vascular complications in the course of their disease and we review the existing literature.
{"title":"Manifestaciones tromboembólicas en enfermedad inflamatoria intestinal","authors":"A. Campos Ruiz , P. Ramirez de la Piscina Urraca , I. Ganchegui Aguirre , L. Urtasun Arlegui , A. Sanchez Patón , K. Spicakova , I.M. Duca Duca , S. Estrada Oncins , E. Delgado Fontaneda , M. Salvador Perez , B. Rodriguez Vigil","doi":"10.1016/j.eii.2015.08.002","DOIUrl":"10.1016/j.eii.2015.08.002","url":null,"abstract":"<div><p>Inflammatory bowel disease (IBD) is a systemic chronic disease, which in some cases is associated with thromboembolic events. Although these events are uncommon, they are increased in patients with IBD and increase morbidity and mortality.While IBD is active there are modifications in the coagulation system, thus inducing a hypercoagulable state and a risk of developing thrombotic events which are not present in patients with inactive IBD.It is essential to identify which patients have a higher risk of developing a thrombotic event and establish appropriate prophylaxis as early as possible.We present some cases of patients diagnosed with IBD who developed vascular complications in the course of their disease and we review the existing literature.</p></div>","PeriodicalId":100473,"journal":{"name":"Enfermedad Inflamatoria Intestinal al Día","volume":"14 3","pages":"Pages 81-86"},"PeriodicalIF":0.0,"publicationDate":"2015-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.eii.2015.08.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78192477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-09-01Epub Date: 2015-10-01DOI: 10.1016/j.eii.2015.08.001
J. Panés
{"title":"Cómo los estudios traslacionales asociados a ensayos clínicos pueden mejorar nuestro conocimiento de las enfermedades inflamatorias","authors":"J. Panés","doi":"10.1016/j.eii.2015.08.001","DOIUrl":"10.1016/j.eii.2015.08.001","url":null,"abstract":"","PeriodicalId":100473,"journal":{"name":"Enfermedad Inflamatoria Intestinal al Día","volume":"14 3","pages":"Pages 79-80"},"PeriodicalIF":0.0,"publicationDate":"2015-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.eii.2015.08.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76435682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-09-01Epub Date: 2015-10-01DOI: 10.1016/j.eii.2015.09.001
S. Riestra , C. Taxonera , D. Carpio , A. López-San Román , J.P. Gisbert , E. Domènech , en representación de GETECCU
The use of antibodies against tumor necrosis factor alpha (anti-TNF) increases the risk of tuberculosis (TB) in patients with inflammatory bowel diseases (IBD). The Spanish Working Group in IBD (GETECCU) developed the first guidelines for TB screening in IBD in 2003, and they were further reviewed in 2006. However, the widespread use in clinical practice of new diagnostic tools such as interferon-gamma release assays, the better knowledge of epidemiological and clinical features of TB in the setting of anti-TNF therapy, and the evidence that TB has decreased but still occurs despite the implementation of guidelines for the screening of latent TB infection, prompted a new revision of the GETECCU recommendations.
{"title":"Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el cribado y tratamiento de la tuberculosis latente en pacientes con enfermedad inflamatoria intestinal","authors":"S. Riestra , C. Taxonera , D. Carpio , A. López-San Román , J.P. Gisbert , E. Domènech , en representación de GETECCU","doi":"10.1016/j.eii.2015.09.001","DOIUrl":"10.1016/j.eii.2015.09.001","url":null,"abstract":"<div><p>The use of antibodies against tumor necrosis factor alpha (anti-TNF) increases the risk of tuberculosis (TB) in patients with inflammatory bowel diseases (IBD). The Spanish Working Group in IBD (GETECCU) developed the first guidelines for TB screening in IBD in 2003, and they were further reviewed in 2006. However, the widespread use in clinical practice of new diagnostic tools such as interferon-gamma release assays, the better knowledge of epidemiological and clinical features of TB in the setting of anti-TNF therapy, and the evidence that TB has decreased but still occurs despite the implementation of guidelines for the screening of latent TB infection, prompted a new revision of the GETECCU recommendations.</p></div>","PeriodicalId":100473,"journal":{"name":"Enfermedad Inflamatoria Intestinal al Día","volume":"14 3","pages":"Pages 109-119"},"PeriodicalIF":0.0,"publicationDate":"2015-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.eii.2015.09.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87331770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-09-01Epub Date: 2015-10-21DOI: 10.1016/j.eii.2015.08.005
D. Carpio
{"title":"Más allá de la curación mucosa endoscópica en la colitis ulcerosa: la remisión histológica predice mejor la utilización de corticoides y la necesidad de hospitalización durante 6 años de seguimiento","authors":"D. Carpio","doi":"10.1016/j.eii.2015.08.005","DOIUrl":"10.1016/j.eii.2015.08.005","url":null,"abstract":"","PeriodicalId":100473,"journal":{"name":"Enfermedad Inflamatoria Intestinal al Día","volume":"14 3","pages":"Pages 120-123"},"PeriodicalIF":0.0,"publicationDate":"2015-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.eii.2015.08.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83467479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-05-01Epub Date: 2015-08-19DOI: 10.1016/j.eii.2015.05.001
A. Gutiérrez Casbas
{"title":"Comentarios sobre estudios multicéntricos aleatorizados para colitis ulcerosa en fase IIa","authors":"A. Gutiérrez Casbas","doi":"10.1016/j.eii.2015.05.001","DOIUrl":"10.1016/j.eii.2015.05.001","url":null,"abstract":"","PeriodicalId":100473,"journal":{"name":"Enfermedad Inflamatoria Intestinal al Día","volume":"14 2","pages":"Pages 76-78"},"PeriodicalIF":0.0,"publicationDate":"2015-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.eii.2015.05.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91489775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-05-01Epub Date: 2015-08-19DOI: 10.1016/j.eii.2015.06.002
D. Ginard , I. Marín-Jiménez , M. Barreiro de Acosta , E. Ricart , E. Domènech , J.P. Gisbert , M. Esteve , M. Mínguez , en representación de GETECCU
Although most patients with ulcerative colitis should be treated with topical treatment, different studies have shown that they are underused. The purpose of this article is to answer 10 specific questions about which drugs are available for topical use in the treatment of ulcerative colitis, and their characteristics in terms of formulation, dosage, presentation, application and proximal distribution of rectal-administered drugs. The efficacy of the available topical drugs and the benefits of combining different formulations and routes of administration, and their usefulness during disease remission is evaluated. Finally, some recommendations are given to better inform patients about the proper implementation and administration of topical treatment.
{"title":"Recomendaciones sobre el uso e indicaciones del tratamiento tópico en pacientes con colitis ulcerosa","authors":"D. Ginard , I. Marín-Jiménez , M. Barreiro de Acosta , E. Ricart , E. Domènech , J.P. Gisbert , M. Esteve , M. Mínguez , en representación de GETECCU","doi":"10.1016/j.eii.2015.06.002","DOIUrl":"https://doi.org/10.1016/j.eii.2015.06.002","url":null,"abstract":"<div><p>Although most patients with ulcerative colitis should be treated with topical treatment, different studies have shown that they are underused. The purpose of this article is to answer 10 specific questions about which drugs are available for topical use in the treatment of ulcerative colitis, and their characteristics in terms of formulation, dosage, presentation, application and proximal distribution of rectal-administered drugs. The efficacy of the available topical drugs and the benefits of combining different formulations and routes of administration, and their usefulness during disease remission is evaluated. Finally, some recommendations are given to better inform patients about the proper implementation and administration of topical treatment.</p></div>","PeriodicalId":100473,"journal":{"name":"Enfermedad Inflamatoria Intestinal al Día","volume":"14 2","pages":"Pages 41-47"},"PeriodicalIF":0.0,"publicationDate":"2015-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.eii.2015.06.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137161896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-05-01Epub Date: 2015-08-19DOI: 10.1016/j.eii.2015.05.003
E. Cerrillo, B. Beltrán
{"title":"Alelo de riesgo ATG16L1 y estrés del retículo endoplásmico de las células de Paneth en la enfermedad de Crohn inactiva","authors":"E. Cerrillo, B. Beltrán","doi":"10.1016/j.eii.2015.05.003","DOIUrl":"10.1016/j.eii.2015.05.003","url":null,"abstract":"","PeriodicalId":100473,"journal":{"name":"Enfermedad Inflamatoria Intestinal al Día","volume":"14 2","pages":"Pages 72-73"},"PeriodicalIF":0.0,"publicationDate":"2015-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.eii.2015.05.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90121460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-05-01Epub Date: 2015-08-19DOI: 10.1016/j.eii.2015.07.001
A. Hadad
{"title":"SMAD7: un oligonucleótido antisentido oral para el tratamiento de la enfermedad de Crohn","authors":"A. Hadad","doi":"10.1016/j.eii.2015.07.001","DOIUrl":"10.1016/j.eii.2015.07.001","url":null,"abstract":"","PeriodicalId":100473,"journal":{"name":"Enfermedad Inflamatoria Intestinal al Día","volume":"14 2","pages":"Pages 39-40"},"PeriodicalIF":0.0,"publicationDate":"2015-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.eii.2015.07.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75362703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-05-01Epub Date: 2015-08-19DOI: 10.1016/j.eii.2015.06.006
N. Manceñido Marcos
The use of Complementary and Alternative Medicine (CAM) in Inflammatory Bowel Disease (IBD) patients is very common. Complementary and alternative therapies might be effective for the treatment of IBD, although they might be as well potentially dangerous. Nowadays, the evidence and information about these types of therapies are not enough. However, alternative treatment strategies are limited and require extensive clinical testing before being optimized for use in patients. Therefore, physicians should know and increasingly inform IBD patients about benefits and limitations of CAM treatment. A review of clinical evidence available on the different types of CAM used in IBD is made.
{"title":"Medicina alternativa y complementaria en la enfermedad inflamatoria intestinal","authors":"N. Manceñido Marcos","doi":"10.1016/j.eii.2015.06.006","DOIUrl":"10.1016/j.eii.2015.06.006","url":null,"abstract":"<div><p>The use of Complementary and Alternative Medicine (CAM) in Inflammatory Bowel Disease (IBD) patients is very common. Complementary and alternative therapies might be effective for the treatment of IBD, although they might be as well potentially dangerous. Nowadays, the evidence and information about these types of therapies are not enough. However, alternative treatment strategies are limited and require extensive clinical testing before being optimized for use in patients. Therefore, physicians should know and increasingly inform IBD patients about benefits and limitations of CAM treatment. A review of clinical evidence available on the different types of CAM used in IBD is made.</p></div>","PeriodicalId":100473,"journal":{"name":"Enfermedad Inflamatoria Intestinal al Día","volume":"14 2","pages":"Pages 57-64"},"PeriodicalIF":0.0,"publicationDate":"2015-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.eii.2015.06.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87232092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}